Is ATAI Life Sciences NV (ATAI) Stock About to Get Hot Thursday?

ATAI Life Sciences NV (ATAI) stock has gained 3.20% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

ATAI Life Sciences NV has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ATAI!

See Full ATAI Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ATAI Stock Today?

ATAI Life Sciences NV (ATAI) stock is lower by -5.5% while the S&P 500 has risen 0.05% as of 9:55 AM on Thursday, Oct 19. ATAI has fallen -$0.07 from the previous closing price of $1.36 on volume of 137,605 shares. Over the past year the S&P 500 has gained 16.04% while ATAI has fallen -54.42%. ATAI lost -$0.92 per share in the over the last 12 months. To screen for more stocks like ATAI Life Sciences NV click here.

More About ATAI Life Sciences NV

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany. Click Here to get the full Stock Report for ATAI Life Sciences NV stock.